Publication for MS4A1 and CD22

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	MS4A1	membrane spanning 4-domains A1	931			[link]
hsa	CD22	CD22 molecule	933

Pubmed ID	Priority	Text
25998714	0.98	CD20, CD22, CD37, and CD45.
	0.97	CD22) combined with veltuzumab (anti-CD20).
	0.86	CD20, CD22, and human leukocyte antigen-DR (HLA-DR) for B-cell non-Hodgkin's lymphoma (B-NHL); CD33 and CD45 for acute myeloid leukemia (AML) (Figure 1); and PSMA and the extra domain B (ED-B) of fibronectin for solid tumours.
30233192	0.98	CD20, CD22, and thymic stromal lymphopoietin receptor.
	0.97	CD20 simultaneously has shown encouraging results, while a separate bispecific CAR targeting CD19 and CD22 is currently being tested in an ongoing clinical trial (NCT03241940).
22645714	0.98	CD20, and CD22 expressed by normal B-cells.
22864478	0.98	CD20, HER2, EGFR, VEGFA, EpCAM, and CTLA-4), (b) pre-validated targets (e.g., IGF-1R, IGF1/2, HGF, c-Met, Her3, VEGF/VEGF-R, Trail-R, IL6/IL6R, IL4/IL13, CD19, CD22, CD30, CD33, CD44, CD80 min CXCR4, and ICAM-1), and (c) new functional targets (e.g., RAAG12, CD9, JAM-A, CD151, TSN-1).
25853860	0.98	CD20-, CD22-, CD23-, CD25-, CD27-, CD40-, CD52-, CD56-, CD79b- and FMC7- (Fig 1).
24225748	0.97	CD20 (Rituximab), anti-CD52 (Alemtuzumab), anti-CD22 (BL22, HA22) and anti-CD25 (Oncotac) are mainstay therapeutic options or in pre-clinical development for the treatment of chronic lymphocytic leukemia (CLL).
	0.97	CD20, CD22, CD25 and CD52 in CLL cells from 28 untreated patients.
	0.97	CD20, CD22 and CD52 but 4 (14%) cases were negative for CD25.
	0.89	CD20, CD22, CD25 and CD52 by fresh CLL cells in 28 untreated patients.
	0.86	CD20, CD22, CD25 and CD52 ABC values with the absolute B-cell counts at presentation (data not shown).
	0.75	CD20 (p=0.030), CD20 > CD22 (p<0.0001), CD22 > CD25 (p<0.0001)
	0.61	CD20 and CD52 are currently important therapeutic targets in this disease with CD22, CD25 and more recently CD23 being explored as potential targets in research protocols.
	0.53	CD20, CD22, CD25 and CD52 ABC values were observed in different cases.
21347809	0.97	CD20 and CD22 using veltuzumab and epratuzumab, respectively, and these BsAbs demonstrated enhanced efficacy when compared to the parent mAbs.
	0.94	CD20/CD22 bispecific mAb was developed and tested in the same in vitro and in vivo models.
	0.93	CD20, CD22, and BCR into lipid rafts and the effects of BsAb-induced localization of BCR into lipid rafts resembles that caused by anti-IgM. In addition, CD22 undergoes internalization once bound by ligand, while CD20 does not.
	0.88	CD22 to CD20, a CD20/CD22 BsAb prevents CD22 internalization, which likely affects downstream signaling.
	0.77	CD20 and CD22.
	0.70	CD20/CD22 bispecific antibody (Bs20x22) maintained binding characteristics similar to the parent mAbs, 293T cells were transfected with either CD20 or CD22 and stained with Bs20x22 or a parent mAb.
	0.67	CD20) and HB22.7 (anti-CD22).
20220093	0.97	CD22 target clones are depicted; the Jurkat-CD20 clone densities were: 4,900, 9,200, 11,000, 18,000, 25,000, 34,000, 105,000, 245,000, and 284,000 CD20 ABS/cell.
	0.96	CD22-specific RFB4 cTCR was ~ 4 times greater than that required to inhibit lysis by the CD20-specific Leu16 cTCR.
	0.95	CD22-specific and Leu16 CD20-specific T cells was inhibited in an antigen dose-dependent fashion (Fig. 5B and not depicted).
	0.94	CD20-specific Leu16 cTCR induced maximal lysis at lower antigen densities, but also was maximally inhibited by secondary targets at lower antigen densities than was the CD22-specific RFB4 cTCR.
	0.93	CD20-specific Leu16 or CD22-specific RFB4 cTCR+ T cells were titrated into wells containing 51Cr-labeled Daudi (primary targets) and 30-fold excess of Jurkat T cell clones (secondary targets) expressing varying densities of CD20 or CD22, respectively.
	0.92	CD20-specific Leu16 cTCR+ and CD22-specific RFB4 cTCR+ T cells in the presence of a 30-fold excess of lymphoblastoid cultured lymphocytes (LCL; EBV-transformed B cells expressing CD20 and CD22).
29374074	0.97	B-1 cells 5 days post TNP-Ficoll immunization in WT, CD22-/- and CD22-/-CD19+/- mice.
	0.88	B-1 cells or due to the effect of CD11b on CD22-mediated regulation.
29772458	0.97	CD20, CD22, CD33, and CD52.
	0.95	CD20, and CD22.
23054625	0.97	CD22 is a transmembrane sialoadhesion molecule that is expressed specifically on the surface of activated B cells and memory cells, but like CD20, it is not expressed on differentiated plasma cells.
31205644	0.97	CD20, and CD22 that are currently in clinical use or in early phase clinical trials for patients with ALL is presented in Table 1.
29974035	0.96	CD20, CD22, and IgM) are present with a co-expression of CD10.
	0.78	CD20 followed by CD19, CD22, and CD74 appear to be valid targets for immunotherapy.
	0.64	CD20-, CD19-, and CD22-Specific Antibodies
23565504	0.96	CD20, CD21, CD22, and CD30 (see Table 1 for an overview).
25517315	0.96	CD20 and CD22 appeared to be strongly downregulated with log fold change (Log FC) below -1.584 and P < 0.01 in cells treated with either dasatinib or PP2.
30212602	0.96	CD22 PE/CD34 PerCP-Cy5.5/CD20 PE-Cy7/CD38 Alexa594/CD24 APC/CD45 APC-H7
28515942	0.95	CD20, and CD22 surface expression by flow cytometry.
	0.91	CD20, and CD22 expression levels, respectively, when Raji cells were co-cultured with no T cells (row 1), 19A CAR (row 2), or 2019 CAR (row 3).
	0.89	CD20, and CD22 surface expression by flow cytometry (black, light grey, and dark grey bars, respectively.
	0.88	CD20 and CD22 on Raji cells in a transwell co-culture assay.
	0.86	CD22, and to a lesser degree, of CD20.
	0.84	CD22 or CD20 on Raji cells following co-incubation with CART cells is a direct effect of CAR T-tumor cell contact, or is due to soluble factors released to the medium by CAR T cells.
	0.83	CD20 and CD22.
	0.70	CD20 and CD22 on viable Raji cells (Fig. 8).
	0.67	CD20 and CD22 surface expression (solid, open, gray, respectively) in surviving Raji and NALM-6 cells after overnight or 4 days of co-culture with CAR T cells, as listed on x-axis, as determined by flow cytometry.
	0.65	CD20 and CD22 on Raji surface requires direct contact with CART cells.
	0.63	CD20 was also moderately down-modulated, and close to half of CD22 expression was also lost.
	0.51	CD20 and CD22.
25916583	0.95	CD22 51, or to the redistribution of CD20 into lipid rafts after incubation with RTX 22.
	0.92	CD20 mAb depleted B cells from patients with RA and SLE more efficiently than either type I anti-CD20 or anti-CD22 mAb and that internalization influenced the efficiency of depletion.
	0.86	CD20, including anti-CD19 34 and anti-CD22 mAb 50, which are aimed at depleting B cells and/or modulating their function.
	0.66	CD20 mAb, but not anti-CD22 mAb.
16630358	0.95	CD20, another unique target is CD22, a 135 kDa glycoprotein that is a B-lymphocyte-restricted member of the immunoglobulin superfamily, and a member of the sialoadhesin family of adhesion molecules that regulate B cell activation and interaction with T cells.
29740441	0.95	CD20, and CD22 that can directly target multiple B cell subtypes, but not or only to a lesser extent mature antibody-secreting plasma cells, (II) inhibitors of B cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), two cytokines which are very important survival factors for B cells and plasma cells, respectively, and (III) velcade/bortezomib, a small molecule proteasome inhibitor that spares B cells but eliminates both short-lived and long-lived plasma cells.
23281743	0.93	CD20, anti-CD22 and anti-CD52 therapies (Table 1).
22684281	0.92	CD20, CD22, and CD30, but this is not limited and any new mAb against a previously untargeted antigen may bring a new site to attention.
30603741	0.92	CD20-targeted CAR-T (CART-20) therapy for B-NHL, CD22-targeted CAR-T for B-ALL, CD30-targeted CAR-T (CART-30) for Hodgkin's lymphoma (HL), CD33-targeted CAR-T for acute myeloid leukemia (AML), and B-cell maturation antigen (BCMA)-targeted CAR-T for multiple myeloma (MM) have been widely studied in clinical trials.
27000958	0.91	CD20, CD22, ROR1, IgK, BCMA, CD138, CD33, CD123 and LewisY antigen
27411958	0.90	CD20, CD22 and AID are elevated in primary and metastatic lesions compared with normal skin samples and also elevated in metastatic versus primary melanomas (n = 234, normalized microarray gene expression data from indicated studies, GEO database; One-way ANOVA with Tukey's post hoc test).
	0.87	CD20, CD22 and AID mRNA expression.
	0.79	CD20, CD22, and AID relative expression in primary versus metastatic melanomas (n = 384, TCGA database; T-test with Welch's correction was performed).
	0.78	CD20, CD22 and AID.
21437222	0.89	CD20/CD22 hexavalent antibodies with promising antilymphoma activity in vitro and in vivo.
	0.81	CD20/CD22 hexavalent antibodies, compared to their bivalent parental antibodies, with their increased ability to upregulate PTEN, phospho-p38, and cyclin-dependent kinase inhibitors, such as p21, p27 and Kip2.
	0.59	CD20 plus anti-CD22, anti-CD20 plus anti-HLA-DR, anti-CD20 plus anti-TRAIL-R1, anti-CD20 plus anti-CD80 have been evaluated preclinically and/or clinically, showing enhanced antitumor activity both in vitro and in vivo.
25484043	0.89	CD20, which also interacts with BCR and affects calcium mobilization and its own degradation, the expression levels of CD22 as well as BCR on the cell surface may be critical for the activity of anti-CD22 mAbs, and needs further investigation.
31637014	0.89	CD20 CAR-T cells have been evaluated for efficacy and safety, and preclinical investigations have demonstrated similar anti-lymphoma activity compared to CD22 CAR-T cell therapy.
17991300	0.88	CD20, CD22 or CD79b (Table I); nor did CD21 expression correlate with uptake of antibodies to any of those proteins (data not shown).
22566889	0.88	CD20/anti-CD22 bispecific mAbs (Rossi et al.,).
32012891	0.88	CD20 (rituximab), CD19 (blinatumomab), and CD22 (inotuzumab)), have become available in Europe and USA, thus changing the treatment protocol for B-ALL patients.
25355407	0.86	CD20 mAb that was constructed on the framework regions of the anti-CD22 mAb epratuzumab (see below).
31798590	0.84	CD22, CD20, CD10, CD34, CD38, and CD45).
30761128	0.83	CD22 likely functions differently between innate-like B-1 and conventional B-2 cells since CD22 is differentially regulated after BCR-mediated and -independent activation in these B cell lineages.
31616632	0.83	CD20, CD19, CD22, CD10.
32195000	0.79	CD20, and CD22 have begun for the treatment of B-NHLs.
28821272	0.77	CD20, CD22, and CD52 are the main markers presented in the majority of B ALL patients and thus are targeted in immunotherapies.
	0.75	CD20, CD22, or CD52, immunotherapy has been demonstrating promising clinical results.
19825447	0.74	CD20, CD22, CD10, Bcl-6, and CD79a (negative for CD5, CD23, Bcl-2, and nuclear terminal deoxyribonucleotide transferase [TdT]).
	0.59	CD20, CD22, CD33 or CD52, which can be targeted by specific monoclonal antibodies (MoAbs).
22084681	0.59	CD22, while FdA up-regulated CD20, CD54, CD80, CD86 and CD95.
29385713	0.58	CD20 and/or CD22 for the treatment of B cell leukemias or CLL-1, CD33 and/or CD123 for the treatment of acute myeloid leukemia.
19359050	0.53	CD22 and whole CD20 antibodies were covalently linked.